Recursion Pharmaceuticals is trading at $3.79, up 4.35%, with no specific catalyst established. - No new company announcement was found for November 4; the latest company releases were November 2 earnings and clinical updates. - The gain coincides with a broader risk-on session and biotech rally, with XBI up 2.13%; available reporting does not establish a specific catalyst for the move. - Recent results included positive REC-4881 data and a longer cash runway, but preceded today’s trading.